The Federal Trade Commission will hold a public workshop June 18 in Washington, D.C., to assess the impact of certificates of public advantage on health care prices, quality, access and innovation. “States have enacted COPAs with the assumption that regulatory oversight can mitigate the effects of lost competition and may allow hospitals to achieve certain efficiencies,” FTC said. “The Commission is interested in empirical research on the actual benefits and harms associated with COPAs, and on qualitative analyses of stakeholders’ experience with COPAs. Such studies and analyses, as well as the information presented at this workshop, may help advance the agency’s policy and enforcement strategies.” The workshop is part of FTC’s COPA Assessment Project.

Related News Articles

Headline
Medicaid enrollment decreased 7.6% in fiscal year 2025 and is expected to be mostly flat in FY 2026, according to KFF’s annual Medicaid Budget Survey released…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The AHA collaborated with LCMC Health in New Orleans to spotlight innovative efforts that extend care beyond hospital walls. LCMC Health supports families…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…